etanidazole has been researched along with Glioma in 12 studies
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.
etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the toxicity and maximum tolerated dose of etanidazole administered concurrently with hyperfractionated radiation therapy (HRT) for children with brainstem glioma." | 9.10 | A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. ( Barnes, P; Billett, AL; Coleman, CN; Dutton, SC; Goumnerova, L; Kieran, M; Marcus, KJ; Pomeroy, SL; Tarbell, NJ, 2003) |
| "To determine the maximum tolerable total dose (MTD) of etanidazole (ETA) when administered with external beam radiotherapy (XRT) and as a continuous infusion during stereotactic brachytherapy for patients with malignant glioma (anaplastic astrocytoma or glioblastoma multiforme or mixed cell tumors)." | 9.07 | A phase I study of etanidazole and radiotherapy in malignant glioma. ( Alexander, E; Black, PM; Coleman, CN; Loeffler, JS; Riese, NE; Wen, P, 1994) |
| "To determine the toxicity and maximum tolerated dose of etanidazole administered concurrently with hyperfractionated radiation therapy (HRT) for children with brainstem glioma." | 5.10 | A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. ( Barnes, P; Billett, AL; Coleman, CN; Dutton, SC; Goumnerova, L; Kieran, M; Marcus, KJ; Pomeroy, SL; Tarbell, NJ, 2003) |
| "To determine the maximum tolerable total dose (MTD) of etanidazole (ETA) when administered with external beam radiotherapy (XRT) and as a continuous infusion during stereotactic brachytherapy for patients with malignant glioma (anaplastic astrocytoma or glioblastoma multiforme or mixed cell tumors)." | 5.07 | A phase I study of etanidazole and radiotherapy in malignant glioma. ( Alexander, E; Black, PM; Coleman, CN; Loeffler, JS; Riese, NE; Wen, P, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marotta, D | 1 |
| Karar, J | 1 |
| Jenkins, WT | 7 |
| Kumanova, M | 1 |
| Jenkins, KW | 1 |
| Tobias, JW | 1 |
| Baldwin, D | 1 |
| Hatzigeorgiou, A | 1 |
| Alexiou, P | 1 |
| Evans, SM | 7 |
| Alarcon, R | 1 |
| Maity, A | 1 |
| Koch, C | 1 |
| Koumenis, C | 1 |
| Ziemer, LS | 1 |
| Kachur, AV | 1 |
| Shuman, AL | 1 |
| Cardi, CA | 1 |
| Karp, JS | 1 |
| Alavi, A | 1 |
| Dolbier, WR | 1 |
| Koch, CJ | 6 |
| Marcus, KJ | 1 |
| Dutton, SC | 1 |
| Barnes, P | 1 |
| Coleman, CN | 2 |
| Pomeroy, SL | 1 |
| Goumnerova, L | 1 |
| Billett, AL | 1 |
| Kieran, M | 1 |
| Tarbell, NJ | 1 |
| Judy, KD | 1 |
| Dunphy, I | 1 |
| Hwang, WT | 1 |
| Nelson, PT | 1 |
| Lustig, RA | 1 |
| Jenkins, K | 1 |
| Magarelli, DP | 1 |
| Hahn, SM | 1 |
| Collins, RA | 1 |
| Grady, MS | 1 |
| Vordermark, D | 1 |
| Kumar Naraharisetti, P | 1 |
| Yung Sheng Ong, B | 1 |
| Wei Xie, J | 1 |
| Kam Yiu Lee, T | 1 |
| Wang, CH | 1 |
| Sahinidis, NV | 1 |
| Joiner, B | 2 |
| Laughlin, KM | 1 |
| Lord, EM | 2 |
| Riese, NE | 1 |
| Loeffler, JS | 1 |
| Wen, P | 1 |
| Alexander, E | 1 |
| Black, PM | 1 |
| Shapiro, M | 1 |
| Rasey, JS | 1 |
| Hofstrand, PD | 1 |
| Chin, LK | 1 |
| Tewson, TJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer[NCT01881451] | 5 participants (Actual) | Observational | 2013-08-31 | Terminated (stopped due to Due to slow accrual and access to the study drug.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for etanidazole and Glioma
| Article | Year |
|---|---|
A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
Topics: Adolescent; Adult; Antineoplastic Agents; Astrocytoma; Brain Stem Neoplasms; Child; Child, Preschool | 2003 |
A phase I study of etanidazole and radiotherapy in malignant glioma.
Topics: Adult; Aged; Brachytherapy; Brain Neoplasms; Etanidazole; Female; Glioma; Humans; Male; Middle Aged | 1994 |
10 other studies available for etanidazole and Glioma
| Article | Year |
|---|---|
In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection.
Topics: Animals; Cell Hypoxia; Etanidazole; Gene Expression Profiling; Gene Expression Regulation, Neoplasti | 2011 |
Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
Topics: Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Etanidazole; Feasibility Studies; Fluorine Radiois | 2003 |
Hypoxia is important in the biology and aggression of human glial brain tumors.
Topics: Aged; Brain Neoplasms; Electrodes; Etanidazole; Glioma; Humans; Hydrocarbons, Fluorinated; Hypoxia; | 2004 |
Significance of hypoxia in malignant glioma. Re: Evans et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84.
Topics: Antineoplastic Agents; Brain Neoplasms; Etanidazole; Glioma; Humans; Hydrocarbons, Fluorinated; Hypo | 2005 |
In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Cell Line, Tumor; Drug Delivery | 2007 |
Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide].
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Hypoxia; Etanidazole; Fluorescence; Gli | 1995 |
2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Hypoxia; Etanidazole; Glioma; Hydrocarb | 1996 |
Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status.
Topics: Animals; Benzimidazoles; Cell Hypoxia; Cell Survival; Etanidazole; Fluorescent Dyes; Glioma; Humans; | 1997 |
Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
Topics: Animals; Binding Sites; Blood-Brain Barrier; Cell Hypoxia; Chromatography, High Pressure Liquid; Con | 1999 |
Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode.
Topics: Animals; Cell Hypoxia; Etanidazole; Glioma; Hydrocarbons, Fluorinated; Indicators and Reagents; Ion- | 2000 |